Biotics may support psoriasis care by shifting the gut microbiome and lowering inflammatory signals linked to skin disease. In a recent review, randomized trials reported improvements in gut bacteria, inflammatory markers such as CRP, TNF, IL-6, IL-1β, LPS, and IL-17, and psoriasis severity scores.

The signal is promising, but the evidence remains early because the trials were small, varied, and not yet definitive.

Study Details

Psoriasis is not just a skin condition. It is a chronic immune-mediated inflammatory disease that can involve systemic inflammation, metabolic risk, joint disease, and quality-of-life burden. Researchers are increasingly studying the gut-skin axis, the idea that intestinal microbes, gut barrier function, and immune regulation may influence inflammatory skin diseases such as psoriasis.

The Medscape Europe report summarized a review published in Nutrition Reviews that evaluated whether biotics could serve as an adjunctive therapy for psoriasis. The interventions included probiotics, prebiotics, synbiotics, and postbiotics. These approaches are not intended to replace topical therapy, phototherapy, systemic agents, or biologics, but they may become part of a broader supportive strategy for selected patients.

For patients, the practical message is simple: gut health may matter in psoriasis, but supplements are not a cure. For clinicians, the more important question is whether future trials can identify which formulations, doses, durations, and patient phenotypes are most likely to respond.

Methodology

The review included randomized controlled trials published between 2013 and 2024 that tested biotic interventions in people with psoriasis. Most studies evaluated lactic acid bacteria, especially Lactobacillus and Bifidobacterium species, often paired with prebiotic fibers such as inulin or oligosaccharides.

The studies looked at changes in gut microbiota, inflammatory biomarkers, and clinical severity. Psoriasis severity was commonly assessed using PASI, the Psoriasis Area and Severity Index. This score helps quantify how much skin is affected and how inflamed, thickened, and scaly the plaques are.

Key Findings

• Some formulations increased beneficial gut bacteria, including Lactobacillus species and Parabacteroides species.

• Several trials reported lower inflammatory markers, including CRP, TNF, IL-6, IL-1β, LPS, and IL-17. These markers are relevant because psoriasis is driven by immune activation, not just surface-level skin irritation.

• Clinical severity often improved, with reductions in PASI scores reported after several weeks of supplementation. A recent umbrella review also found that probiotics were associated with reduced PASI scores, higher PASI 75 response rates, lower inflammatory biomarkers, and improved Dermatology Life Quality Index scores.

• One notable trial used heat-inactivated Prevotella histicola, suggesting that even nonviable bacteria or bacterial components may have immune effects. This supports growing interest in postbiotics, not only live probiotics.

• The biggest limitation is evidence quality. The Medscape summary noted that only 10 randomized controlled trials met the review criteria, each enrolling fewer than 30 participants, with different protocols, formulations, and outcome measures.

Implications for Practice

For patients, biotics should be viewed as a possible add-on, not a replacement for prescribed psoriasis therapy. Someone with mild psoriasis may be interested in discussing probiotic or fiber-based strategies with their clinician. Someone with moderate to severe disease, psoriatic arthritis, extensive plaques, nail disease, or major quality-of-life impairment should not delay proven treatments while trying supplements.

For healthcare providers, this review strengthens the rationale for discussing diet, fiber intake, metabolic health, and gut health as part of psoriasis care. The most defensible clinical position today is cautious integration: encourage a high-fiber, metabolically healthy dietary pattern, consider biotics in selected patients, and avoid promising disease control from supplements alone.

The next step is precision. Future trials need larger sample sizes, standardized formulations, longer follow-up, and biomarker-driven patient selection. Key unanswered questions include which psoriasis phenotypes respond best, whether response differs in patients with obesity or metabolic syndrome, and whether microbiome patterns can predict benefit.

Bottom Line

Biotics may help some people with psoriasis by improving gut microbial balance and reducing immune inflammation. The current evidence is encouraging but not practice-changing on its own. Patients should see this as a supportive option to discuss with their dermatologist, while clinicians should see it as a signal that the gut-skin axis deserves more rigorous study.

For people newly diagnosed with relapsing multiple sclerosis, rituximab was noninferior to ocrelizumab in preventing new or enlarging brain MRI lesions over 2 years. The trial does not prove the drugs are identical in every way, but it gives clinicians stronger randomized evidence that rituximab may be a practical first-line anti-CD20 option where access, affordability, and payer policy matter.

Study Details

Multiple sclerosis is an immune-mediated disease in which the body attacks the central nervous system. In relapsing MS, patients can experience episodes of neurologic symptoms followed by partial or full recovery, while MRI scans may show ongoing inflammatory activity even when symptoms are quiet.

Ocrelizumab is an approved anti-CD20 therapy for relapsing and primary progressive forms of MS. Rituximab also targets CD20-positive B cells, but it has long been used off-label for MS despite being formally approved for other diseases such as certain blood cancers and autoimmune conditions.

The practical question has been whether an older, often cheaper anti-CD20 drug can deliver similar disease control to a newer approved MS therapy.

The OVERLORD-MS trial directly tested that question in newly diagnosed relapsing MS. This is important because prior comparisons between rituximab and ocrelizumab often relied on observational data, which can be affected by differences in patient selection, prior treatment history, and local prescribing patterns. The clinical trial record described OVERLORD-MS as a prospective, randomized, double-blind, multicenter noninferiority study in treatment-naïve relapsing-remitting MS patients diagnosed within the prior 12 months.

Methodology

Researchers enrolled adults in Sweden and Norway with newly diagnosed relapsing MS and recent disease activity. Participants were randomly assigned to receive rituximab or ocrelizumab every 6 months for 24 months. Patients who had already used MS disease-modifying therapy were excluded, which makes the study especially relevant to first-treatment decisions.

The primary endpoint was MRI-based: absence of new or enlarging T2-weighted lesions between months 6 and 24. This matters because MRI lesions can signal ongoing inflammatory disease activity even when a patient does not have an obvious relapse.

The study was designed as a noninferiority trial. In practical terms, the researchers were not trying to prove rituximab was better than ocrelizumab. They were testing whether rituximab was not meaningfully worse than ocrelizumab by a prespecified margin.

Key Findings

• At 2 years, the estimated probability of having no new or enlarging T2-weighted MRI lesions was 92.2% with rituximab and 94.8% with ocrelizumab.

• The risk difference was -2.6 percentage points, with a 95% confidence interval from -9.4 to 4.3, meeting the trial’s prespecified non inferiority criterion.

• Annualized relapse rates were low in both groups, at 0.09 with rituximab and 0.04 with ocrelizumab.

• Disability progression sustained for at least 6 months occurred in 3% of the rituximab group and 7% of the ocrelizumab group.

• Cognitive performance profiles appeared similar between the two groups.

• Infections were more common with rituximab than with ocrelizumab, occurring in 82% versus 69% of participants, but most were mild upper respiratory infections.

• Serious adverse events were similar between groups, at 8% with rituximab and 7% with ocrelizumab. Serious infections were rare and occurred in four participants in each group. ⁠

Implications for Practice

For patients, the central message is not that anyone should switch therapies on their own. The message is that a lower-cost off-label option now has stronger randomized evidence behind it for newly diagnosed relapsing MS. That may matter for patients facing insurance barriers, high out-of-pocket costs, or limited access to approved branded therapies.

For neurologists, this trial strengthens the case for discussing rituximab as part of the anti-CD20 treatment conversation, especially in health systems where cost-effectiveness and access are major constraints. It also adds pressure to distinguish between regulatory approval, clinical evidence, payer policy, and real-world affordability. A drug can be off-label and still be evidence-supported, but off-label use requires careful consent, monitoring, and documentation.

The infection signal deserves attention. More patients on rituximab had infections, even though most were mild and serious infection rates were similar. In practice, clinicians still need to review vaccination status, infection history, immunoglobulin levels when appropriate, and patient-specific risk factors before starting B-cell depleting therapy.

There are also limits. Follow-up was relatively short for a lifelong disease. The trial was powered for MRI disease activity, not for rare safety events or long-term disability outcomes. Participants were mostly of Northern European ancestry, so generalizability to more diverse populations remains an important question.

The larger takeaway is that MS treatment decisions should not be driven by drug price alone, but price should not be ignored when comparable outcomes are plausible.

This trial gives patients, physicians, and payers a stronger evidence base for a more transparent conversation about value in relapsing MS care.

Two observational studies presented at ASCO 2026 suggest that GLP-1 receptor agonist use is associated with lower breast cancer incidence in women with overweight or obesity.

The larger screened cohort found about a 30% lower incidence after matching, while a high-risk cohort found a more modest 16% reduction. These results are encouraging, but they do not prove that GLP-1 drugs prevent breast cancer.

Study Details

GLP-1 receptor agonists were developed for type 2 diabetes and later became major tools in obesity treatment. Because excess body weight, especially after menopause, is linked to higher breast cancer risk, researchers are now asking whether medications that improve weight and metabolic health may also change cancer risk.

This question matters for patients and clinicians because breast cancer prevention currently depends heavily on screening, lifestyle measures, risk-reducing medications such as tamoxifen for selected high-risk patients, and surgery for a small group with very high genetic risk. A medication already used for obesity and diabetes would be clinically important if it were eventually proven to reduce cancer risk. That proof is not here yet.

The larger study was led by researchers at the University of Pennsylvania and focused on women undergoing breast cancer screening. This is important because prior studies could be criticized for comparing GLP-1 users, who may be more engaged with healthcare, against nonusers who may be screened less often. By studying screened women, the investigators reduced one major source of bias.

A second study used a large real-world database to examine women already considered at higher risk for breast cancer, including those with genetic predisposition, family history, dense breasts, or high-risk breast lesions.

Methodology

The Penn-led study reviewed health records from more than 111,000 women aged 45 to 80 with BMI of 25 or higher who had breast imaging between January 2022 and June 2025. About 15,000 had a documented GLP-1 prescription. Researchers then compared breast cancer diagnoses between GLP-1 users and nonusers, including a matched analysis that balanced key factors such as age, race, ethnicity, BMI, breast density, and diabetes status.

The high-risk study used the TriNetX database and included more than 80,000 women with obesity who had features placing them at elevated breast cancer risk. Researchers compared GLP-1 users with matched nonusers and measured breast cancer incidence over follow-up.

Both studies were observational. That means they can show an association, but they cannot prove cause and effect. Patients taking GLP-1 medications may differ from nonusers in ways that are hard to fully measure, including health behavior, medical follow-up, weight change, medication adherence, insurance access, and underlying metabolic risk.

Key Findings

• In the screened Penn cohort, breast cancer occurred in 1.62% of GLP-1 users compared with 2.31% of matched nonusers.

• After matching, GLP-1 exposure was associated with about 30% lower odds of breast cancer.

• In the high-risk cohort, GLP-1 use was associated with a 16% lower breast cancer incidence.

• The likely explanation is partly weight-loss mediated, since fat tissue, insulin resistance, inflammation, and postmenopausal estrogen production are all connected to breast cancer biology.

• Direct medication effects are possible but unproven. Researchers are exploring whether GLP-1 drugs may influence inflammation, endocrine signaling, adiponectin, insulin pathways, or tumor microenvironment biology.

• The findings are hypothesis-generating and not practice-changing. Randomized clinical trials are needed before GLP-1 drugs can be recommended specifically for breast cancer prevention.

Implications for Practice

For patients, the practical message is not to start a GLP-1 medication only to prevent breast cancer. These drugs have legitimate indications in obesity, overweight with certain complications, and type 2 diabetes, but cancer prevention is not yet an established indication.

For women who already qualify for GLP-1 therapy because of obesity, diabetes, or cardiometabolic risk, this research adds another possible long-term benefit to discuss with a clinician. It should not replace mammograms, breast MRI when indicated, genetic counseling when appropriate, or standard breast cancer risk-reduction strategies.

For healthcare providers, these findings support a broader view of obesity treatment. GLP-1 therapy should not be framed only as weight loss. It may also affect downstream disease risk through metabolic, inflammatory, vascular, and hormonal pathways. Still, the data should be communicated carefully. The right phrase is “associated with lower breast cancer incidence,” not “prevents breast cancer.”

The screened-cohort design is a strength because it reduces detection bias, but it does not eliminate confounding. The lack of complete adjustment for family history, genetic risk, medication duration, weight-loss magnitude, breast cancer subtype, and GLP-1 drug type limits interpretation. Future trials should stratify by menopausal status, baseline breast cancer risk, diabetes status, breast density, weight change, and hormone receptor subtype.

The deeper clinical question is whether GLP-1 therapy reduces breast cancer risk because it lowers body weight, because it changes cancer-related biology, or because both mechanisms occur together. That distinction matters. If the benefit is mostly weight-loss mediated, then sustained weight reduction through multiple approaches may be the key. If there are direct anti-inflammatory or endocrine effects, GLP-1 drugs may eventually have a more specific prevention role.

What Patients Should Ask Their Clinician

Patients with overweight or obesity who are worried about breast cancer risk should ask about their personal risk profile, including family history, breast density, menopausal status, prior biopsies, genetic testing, alcohol use, physical activity, and metabolic health. GLP-1 medications may be part of a broader obesity or diabetes treatment plan, but they should not be treated as a substitute for screening or individualized breast cancer prevention care.

Bottom Line

These two ASCO 2026 studies strengthen the signal that GLP-1 receptor agonists may be associated with lower breast cancer incidence in women with overweight or obesity. The signal is clinically interesting and biologically plausible, but it remains unproven.

The next step is not a new prevention recommendation. The next step is a randomized trial.

A new phase 2 clinical trial found that adding apitegromab, an investigational antibody that blocks myostatin activation, helped adults taking tirzepatide lose less lean body mass while achieving similar total weight loss.

The finding matters because patients using GLP-1 and GLP-1/GIP medications often ask whether rapid weight loss means losing too much muscle. This study suggests muscle-preserving add-on therapy may become part of obesity medicine, but it is not ready to replace protein intake, resistance training, or careful clinical monitoring.

Study Details

Tirzepatide has changed obesity treatment by producing substantial weight loss in many patients. But weight loss is not only fat loss. Lean body mass, which includes skeletal muscle, bone, organs, connective tissue, and body water, can also decline during treatment.

That concern has become more visible as GLP-1 based therapies move from specialist obesity clinics into primary care, endocrinology, cardiology, and metabolic medicine. For patients, the fear is practical: will weight loss make me weaker, less functional, or more likely to regain fat later? For clinicians, the question is whether body composition should become a more formal part of obesity treatment planning.

Apitegromab targets myostatin, a protein that normally limits skeletal muscle growth. By inhibiting myostatin activation, the drug is designed to preserve or increase muscle-related tissue. In this study, researchers tested whether that biology could improve the quality of weight loss during tirzepatide treatment.

Methodology

The EMBRAZE trial was a randomized, double-blind, placebo-controlled phase 2 study conducted in adults with overweight or obesity. A total of 102 participants were assigned to receive tirzepatide plus apitegromab or tirzepatide plus placebo for 24 weeks.

Both groups received tirzepatide. The difference was whether participants also received apitegromab or placebo by intravenous infusion every 4 weeks. Tirzepatide was started at 2.5 mg weekly and increased according to the usual dose-escalation schedule as tolerated.

Researchers used DEXA scans to measure body composition before and after treatment. The primary question was whether apitegromab reduced the amount of lean body mass lost during tirzepatide-induced weight loss. The study also tracked body weight, fat mass, adverse events, exploratory physical function measures, and follow-up body composition after treatment ended.

Key Findings

• Total weight loss was similar in both groups. Participants receiving tirzepatide plus apitegromab lost about 11.2 kg, while those receiving tirzepatide plus placebo lost about 12.5 kg.

• Lean body mass accounted for a smaller share of total weight loss with apitegromab. In the apitegromab group, lean mass represented 14.6% of total weight loss, compared with 30.2% in the placebo group.

• Participants receiving apitegromab lost 1.9 kg less lean body mass than those receiving placebo at 24 weeks. This represented a 54.9% relative preservation of lean mass compared with placebo.

• Fat mass made up a larger proportion of weight loss in the apitegromab group, suggesting a more favorable body composition profile during treatment.

• The lean mass difference remained partly visible 8 weeks after treatment stopped, although the effect was smaller.

• Adverse events were broadly similar between groups. Nausea, fatigue, and headache were reported more often with apitegromab, but most events were mild and transient.

• The trial did not show clear improvement in physical function or cardiometabolic outcomes over 24 weeks. This is important because preserving lean mass on a scan is not the same as proving stronger muscles, better mobility, or better long-term health.

Implications for Practice

For patients, the message is encouraging but cautious. This study supports the idea that future obesity treatment may focus not only on how many pounds are lost, but also on what kind of tissue is lost. That is a better frame for long-term health than scale weight alone.

But apitegromab is not a do-it-yourself muscle-preservation strategy. It is an investigational antibody in this obesity context, given by infusion in a clinical trial setting. Patients taking tirzepatide, semaglutide, or other GLP-1 based treatments should still prioritize resistance training, adequate dietary protein, sleep, and gradual dose management with their clinician.

For healthcare providers, this trial is a signal that body composition may become a more important endpoint in obesity medicine. DEXA-measured lean mass preservation is biologically plausible and clinically interesting, especially for older adults, frail patients, patients with sarcopenic obesity, and those who struggle to exercise during weight loss.

However, the limitations matter. The study was small, lasted only 24 weeks, included mostly female participants, and excluded patients with diabetes and significant cardiometabolic disease. That means the results may not apply to many real-world patients who receive GLP-1 therapy, including those with type 2 diabetes, cardiovascular disease, chronic kidney disease, or complex obesity-related complications.

The practical takeaway for clinicians is not that every GLP-1 patient needs a myostatin antibody. The better takeaway is that GLP-1 care should become more deliberate: assess strength, function, protein intake, resistance exercise, frailty risk, and weight-regain risk. If larger trials confirm these findings, muscle-preserving therapies may eventually become an add-on option for selected patients.

For now, apitegromab is best viewed as an early proof-of-concept: it may improve the composition of weight loss during tirzepatide therapy, but it has not yet proven that patients feel stronger, function better, avoid frailty, or maintain better metabolic health long term.

Editorial Note

This is not our usual standard article format, which normally stays closer to a single study and its clinical implications. We are taking a more editorial approach here because the recent pushback from parts of the physician community, along with broader anti-AI sentiment in healthcare, misses the most practical point. The question is not whether AI should replace physicians. The question is whether physicians who use AI responsibly will make better decisions than physicians forced to rely only on human attention inside overloaded systems.

Topline

A Nature Medicine case highlighted how an AI-enhanced ECG tool helped physicians detect severe hidden heart disease in a 45-year-old emergency department patient who was initially treated for asthma-like symptoms.

The AI tool, EchoNext, flagged possible structural heart disease from a routine ECG, leading to echocardiography, recognition of severe heart failure, genetic testing, and ultimately heart transplantation.

The central lesson is not that AI replaces doctors. It is that physicians using AI may practice better medicine when symptoms are nonspecific, test results are noisy, and healthcare systems are under pressure.

Study Details

Structural heart disease includes problems affecting the heart valves, walls, chambers, or pumping function. It can present with clear symptoms, but it can also look like something else. Patients may have shortness of breath, fatigue, swelling, fainting, chest discomfort, or poor exercise tolerance. In emergency care, those symptoms often overlap with lung disease, infection, anxiety, anemia, asthma, or other common conditions.

The patient in this case was Louie Quiros, a 45-year-old caregiver and security guard who came to a Queens emergency room after several days of coughing blood and worsening shortness of breath. His chest X-ray was normal. His ECG was abnormal, but not in a way that made the diagnosis obvious. Because he had recently been exposed to wildfire smoke, he was initially sent home with asthma medication and an inhaler.

That emergency department was part of the NewYork-Presbyterian system, where researchers were evaluating EchoNext, an AI-enhanced ECG program developed by clinicians and data scientists at NewYork-Presbyterian and Columbia. EchoNext is designed to analyze ordinary 12-lead ECGs for hidden patterns that may suggest structural heart disease.

In this case, the AI system flagged possible severe heart damage. The patient was called back for echocardiography about a week later. The echocardiogram showed that his heart was pumping extremely poorly, with an ejection fraction of about 10 percent, and that his mitral valve was leaking blood backward into the heart. Further testing found a rare genetic disorder associated with sudden death. He ultimately received a heart transplant.

Methodology

The clinical workflow is straightforward. A patient receives a routine ECG, which is already one of the most common tests in emergency medicine. Instead of using the ECG only to look for rhythm abnormalities or signs of a heart attack, the AI model searches for subtle electrical patterns associated with structural heart disease.

When the AI result suggests high risk, the physician can use that signal to decide whether the patient needs echocardiography. The echocardiogram remains the confirmatory test. The cardiology team still interprets the full clinical picture. The AI does not transplant a heart, diagnose a patient alone, or replace medical judgment.

That distinction matters. Many ECGs are abnormal. Most abnormal ECGs do not mean the patient needs a heart transplant. The real value of AI is helping clinicians decide which abnormal signals deserve escalation. In this case, AI expanded the physician’s field of vision.

Key Findings

• AI-enhanced ECG screening flagged possible structural heart disease in a patient whose symptoms initially looked more like an asthma or lung-related presentation.

• Follow-up echocardiography showed severe heart failure, including an ejection fraction of about 10 percent and mitral valve leakage.

• Further testing identified a rare genetic disorder associated with sudden death, which helped explain the severity of the disease.

• The patient ultimately underwent heart transplantation, showing how an early AI signal can change the diagnostic pathway in a high-risk case.

• The case supports a practical model for medical AI: not autonomous diagnosis, but better physician triage.

• This remains a single case from an ongoing clinical trial, so it should not be interpreted as proof that AI-ECG screening improves outcomes across all patients.

Implications for Practice

For patients, this case is a reminder that shortness of breath, coughing blood, unexplained fatigue, swelling, fainting, or reduced exercise tolerance should not be dismissed when symptoms persist or worsen. A normal chest X-ray does not rule out serious heart disease. An abnormal ECG that does not give a clean diagnosis may still deserve follow-up if the clinical picture does not fit.

For healthcare providers, the case highlights where AI may be most useful. Medicine has an attention problem. Emergency physicians, primary care doctors, and specialists are asked to make difficult decisions under time pressure, often with incomplete information and many competing possibilities. AI can help by surfacing risk that may be easy to miss in a busy workflow.

This is especially important for structural heart disease because echocardiography is not ordered for every patient with an abnormal ECG. That would be expensive, inefficient, and unrealistic. A tool like EchoNext may help identify which patients are most likely to benefit from the next test.

The access story also matters. Reports indicate that EchoNext is expected to become available through OpenEvidence, and the company behind it has announced FDA clearance for multicondition cardiology screening. If implemented carefully, that could move AI-ECG screening beyond a few major academic centers and into broader clinical use.

But implementation needs discipline. Hospitals and clinics will need clear follow-up pathways, cardiology oversight, false-positive management, equity monitoring, and safeguards against treating AI output as a final diagnosis. AI should not be a shortcut around clinical reasoning. It should be a second layer of pattern recognition that helps physicians reason better.

The best version of this future is physician-led AI. The doctor remains accountable. The diagnostic pathway remains clinical. The echocardiogram still confirms disease. But the patient who would otherwise be missed has a better chance of being found.

For the latest in medical research news, check out

Just Healthcare

Join us as we navigate the complex healthcare landscape together. We provide clear, insightful articles on the latest medical research, treatments & innovations tailored for individuals who want to stay informed and empowered about their health journey.

By Naveen Sankar S

Higher daytime light exposure was associated with a lower risk of developing dementia in a large prospective study of more than 87,000 adults. The finding does not prove that light prevents dementia, but it supports a practical message for patients and clinicians: regular bright daytime light may help stabilize circadian rhythms, improve rest activity patterns, and support long term brain health.

Study Details

Dementia prevention is often discussed through blood pressure control, physical activity, hearing care, sleep quality, diabetes management, smoking cessation, and social engagement. This new study adds another possible lifestyle signal: how much light people receive during the day.

The research used UK Biobank data from adults who were free of dementia at baseline. Participants wore wrist devices that measured real world light exposure over 7 days. Researchers then followed participants for a median of 8.1 years to see who developed dementia.

The key exposure was daytime light, especially light above 1,000 lux. That level is roughly similar to being outdoors on an overcast day. Bright daytime light at or above 5,000 lux was also examined, with special attention to whether participants received at least 0.70 hours per day, or about 42 minutes.

Methodology

This was a prospective cohort study, which means researchers measured light exposure before dementia developed and then tracked outcomes over time. That design is stronger than asking people with dementia to remember past habits, but it still cannot prove cause and effect.

The study included 87,577 dementia-free adults. Light exposure was measured using wrist-worn accelerometry. Dementia diagnoses were identified through health records, hospital data, and death registry information.

Researchers adjusted for multiple dementia risk factors and explored possible mediating pathways. In simple terms, they asked whether daytime light might be linked to dementia risk partly through circadian rest activity rhythms or brain structure changes.

Key Findings

• Average daytime light exposure above 1,000 lux was associated with a 16% lower risk of dementia.

• Bright daytime light exposure of at least 5,000 lux for 42 minutes or more per day was also associated with lower dementia risk.

• Nighttime light exposure was not significantly associated with dementia risk in this analysis.

• Circadian rest activity rhythms and certain brain structures appeared to partly explain the relationship.

• Vitamin D did not appear to explain the association, suggesting the signal may be related more to circadian and neural effects than to sun-driven vitamin D production.

• The association appeared stronger in certain high risk groups, including evening chronotypes, people with high nighttime light exposure, and APOE4 carriers.

Implications for Practice

For patients, the practical message is not complicated: getting outside during the day may matter for the brain, not just for mood or sleep. A daily walk, morning light exposure, time near a bright window, or outdoor activity may help reinforce the body’s internal clock.

This does not mean sunlight is a dementia treatment. It also does not replace established prevention strategies such as blood pressure control, exercise, hearing evaluation, diabetes management, smoking cessation, and sleep care. The study is best understood as a low cost prevention signal that fits with what clinicians already know about sleep, circadian rhythm, and brain aging.

For healthcare providers, this study supports adding light exposure to cognitive risk conversations, especially for older adults with poor sleep timing, evening chronotype, limited outdoor activity, depression symptoms, high dementia risk, or disrupted daily routines. A simple clinical question may be useful: “How much bright light do you get during the day?”

A reasonable counseling approach could include 30 to 45 minutes of outdoor daytime light when safe and feasible, preferably earlier in the day. For frail patients, fall risk, heat exposure, skin cancer history, eye disease, photosensitizing medications, migraine sensitivity, and bipolar disorder should be considered before recommending bright light strategies.

The key clinical nuance is that this is an association, not a prescription. The study suggests that daytime light may be a marker and possible modifier of dementia risk. Future trials will need to test whether structured light exposure can reduce dementia incidence or improve intermediate outcomes such as sleep regularity, cognition, mood, and brain imaging markers.

What Patients Can Do Now

A practical goal is to build light into the day rather than treating it like a medical procedure. Morning outdoor time, a walk after breakfast, gardening, sitting on a balcony, or spending time near natural daylight may be realistic starting points.

People who are homebound, shift workers, or living in low light environments may need individualized guidance. Light boxes should be used carefully, especially in people with eye disease, bipolar disorder, or medications that increase light sensitivity.

The best takeaway is simple: the brain appears to care about the timing and brightness of light. Daytime light may help keep the body clock aligned, and an aligned body clock may be one more piece of dementia prevention.

Just Healthcare

Join us as we navigate the complex healthcare landscape together. We provide clear, insightful articles on the latest medical research, treatments & innovations tailored for individuals who want to stay informed and empowered about their health journey.

By Naveen Sankar S

A hysterectomy is often discussed as if it is one standard operation. It is not.

For muscle gain, recovery, strength training, and long-term body composition, the most important question is not simply whether the uterus was removed. The more important question is whether the ovaries were removed.

That distinction changes the physiology.

Removing the uterus is primarily a surgical recovery issue. Removing both ovaries is an endocrine event. It can shift a woman into surgical menopause, with a sudden drop in estrogen and ovarian androgens. That hormonal change can affect sleep, soreness, bone density, joint tolerance, and the pace of training adaptation.

The bottom line is simple: muscle gain is still possible after hysterectomy with ovary removal, but recovery may become less forgiving.

The surgery type matters

A partial hysterectomy, also called a supracervical hysterectomy, removes the uterus but leaves the cervix. If the ovaries are kept, the body usually does not enter immediate menopause.

A total hysterectomy removes the uterus and cervix. Despite the word “total,” this does not automatically mean the ovaries are removed. Many women hear “total hysterectomy” and assume it includes everything. Medically, it may only mean uterus plus cervix.

A hysterectomy with salpingo-oophorectomy includes removal of the uterus and removal of one or both ovaries and fallopian tubes. If both ovaries are removed, the procedure causes surgical menopause in women who have not already gone through menopause.

A bilateral salpingo-oophorectomy removes both ovaries and both fallopian tubes. This is the part that matters most for hormones.

A radical hysterectomy is usually performed for cancer-related reasons. It removes the uterus, cervix, upper vagina, and surrounding tissue. Ovaries may or may not be removed depending on the case.

So the phrase “full hysterectomy” is not precise enough. For training and recovery, the key question is: were the ovaries conserved, one removed, or both removed?

Why the ovaries matter for muscle

The ovaries are not only reproductive organs. They are also hormone-producing organs.

They produce estrogen, progesterone, and androgens. These hormones influence more than menstrual cycles and fertility. They affect muscle repair, connective tissue, sleep quality, fat distribution, inflammation, bone turnover, and training recovery.

When both ovaries are removed before natural menopause, estrogen drops abruptly. That sudden shift is different from the slower hormonal transition of natural menopause.

This matters because estrogen appears to have protective roles in skeletal muscle. It is involved in muscle metabolism, mitochondrial function, inflammation control, and muscle repair signaling. Declining estrogen is also associated with changes in muscle mass, strength, power, and connective tissue resilience.

That does not mean strength training stops working. It means the recovery system has changed.

The latest research is more nuanced than the old story

The old story was too blunt: menopause means decline.

The newer research is more useful. It suggests that the menopausal transition is associated with reductions in lean mass and muscle mass, but it also shows that resistance training still works.

Recent reviews of menopause and skeletal muscle point to changes in muscle protein turnover, estrogen signaling, and anabolic response. Some data suggest that older women may have a less robust muscle-building response to a single training session or protein dose. But the broader training evidence still supports progressive resistance training as one of the strongest interventions for preserving and building muscle after menopause.

A 2023 meta-analysis found that exercise improves body composition in postmenopausal women. Resistance training was more useful for muscle gain. Aerobic training was more useful for fat loss. A combination can help both, but the muscle signal comes mainly from loading.

That is the practical lesson.

After ovary removal, the body may need more deliberate programming. But it still responds to load.

How recovery can change

The first layer is surgical recovery. Any hysterectomy requires tissue healing. Early training has to respect the surgeon’s restrictions, especially around lifting, bracing, intra-abdominal pressure, loaded carries, heavy squats, heavy deadlifts, and aggressive core work.

The second layer is hormonal recovery. This is where ovary removal changes the picture.

After both ovaries are removed, recovery can feel different in several ways.

Sleep may worsen because of hot flashes, night sweats, temperature instability, anxiety, or mood changes. Poor sleep alone can reduce training quality and slow adaptation.

Soreness may last longer. Joint aches may become more noticeable. Tendons and connective tissue may tolerate sudden jumps in volume less well. Training stress that used to be easy to absorb may now require more spacing.

Strength can still improve, but the program may need smaller progressions, better warmups, more consistent protein intake, and planned de-loads.

This is not weakness. It is a different endocrine context.

The training mistake is doing either extreme

One mistake is stopping strength training out of fear.

That is the wrong move. After menopause, and especially after surgical menopause, resistance training becomes more important, not less.

The other mistake is trying to train exactly the same way as before, with the same volume, the same recovery assumptions, and the same tolerance for poor sleep.

That can also backfire.

The better model is not “train less.” It is “train with fewer wasted reps and better recovery discipline.”

What a smarter training approach looks like

The foundation should be progressive resistance training three to four days per week.

The focus should be full-body strength: squat or leg press patterns, hip hinges, rows, presses, pulldowns, step-ups, split squats, and eventually loaded carries when cleared.

The goal is not random exhaustion. The goal is signal.

Most working sets should land close enough to failure to stimulate adaptation, but not so close that every session becomes a recovery crisis. For many people, that means finishing most sets with one to three good reps left in reserve.

Progress should be slower and cleaner. Add reps before adding load. Add load before adding more exercises. Avoid sudden jumps in volume.

Recovery spacing matters. Hitting the same muscle hard every day is usually not the best strategy. Forty-eight to seventy-two hours between hard sessions for the same muscle group is often more sustainable.

De-loads matter too. A lighter week every four to six weeks can help keep progress moving, especially when sleep, soreness, or joint irritation starts to accumulate.

Protein and creatine become more important

Muscle is not built from training alone. Training sends the signal. Nutrition provides the material.

Protein intake becomes more important after menopause because the body may be less responsive to smaller protein doses. A practical target for active women trying to build or preserve muscle is often around 1.6 to 2.2 grams of protein per kilogram of target body weight per day, adjusted for kidney health, total calories, and clinician guidance.

Protein should be distributed across meals rather than saved for one large dinner. Each meal should carry enough protein to matter.

Creatine is also worth considering. A daily dose of three to five grams is simple, inexpensive, and well-supported for strength and lean-mass goals. It is not a hormone. It does not replace training. It helps the muscle energy system do its job.

Bone density is part of the muscle conversation

After both ovaries are removed, bone health becomes part of the training plan.

Lower estrogen accelerates bone loss, especially around the menopausal transition. That makes strength training, impact tolerance, balance, vitamin D status, calcium adequacy, and bone-density monitoring more important.

This is where the conversation should widen beyond “Can I gain muscle?”

The better question is: can the training plan preserve muscle, protect bone, improve balance, and support long-term independence?

That answer is yes, but it requires structure.

Resistance training is not just cosmetic here. It is orthopedic infrastructure.

Hormone therapy belongs in the medical conversation

If both ovaries are removed before the natural age of menopause, hormone therapy should be discussed with a qualified clinician unless there is a contraindication.

Estrogen therapy can help with vasomotor symptoms such as hot flashes and night sweats. It can also help protect against early menopause-related bone loss. If the uterus has been removed, estrogen-only therapy may be an option, because progestogen is mainly used to protect the uterine lining.

This is not a fitness hack. It is medical management of surgical menopause.

Testosterone is a separate issue. Removing both ovaries can lower androgen levels, but major consensus guidance does not support testosterone simply for muscle gain, body composition, energy, or general wellness. The evidence-based indication is much narrower, mainly postmenopausal hypoactive sexual desire disorder after proper assessment.

The important point is that training, nutrition, sleep, bone health, and hormone management should not be treated as separate silos. After ovary removal, they are connected.

The practical answer

A hysterectomy by itself does not prevent muscle gain.

Ovary removal changes the recovery environment.

If the ovaries are kept, the main limitation is usually surgical healing and temporary deconditioning. Once cleared, strength training can usually progress in a fairly standard way.

If one ovary is removed, hormone production may continue, though individual response varies.

If both ovaries are removed, the body enters surgical menopause if menopause has not already occurred. That can make sleep, soreness, joint tolerance, bone density, and muscle adaptation more difficult to manage.

But difficult is not the same as impossible.

The body still adapts to progressive loading. It still responds to protein. It still benefits from consistency. It still builds strength.

The difference is that the training plan must respect the new biology.

Bottom line

The uterus is not the muscle-building organ.

The ovaries are the bigger training variable.

After hysterectomy with both ovaries removed, muscle gain is still achievable, but recovery may become less forgiving because of surgical menopause. The answer is not to avoid training. The answer is to train deliberately: progressive strength work, adequate protein, sleep protection, slower load jumps, bone-density awareness, and medical discussion of hormone therapy when appropriate.

This is the central distinction:

Uterus removed is mainly a surgical recovery issue.

Ovaries removed is a hormonal recovery issue.

That is the piece most people miss.

Tirzepatide produced larger blood sugar reductions than dulaglutide in high-risk adults with type 2 diabetes, but it did not increase diabetic retinopathy development or progression in a 36-month retinal substudy. The findings offer reassurance for patients and clinicians using tirzepatide, while reinforcing the need for routine diabetic eye screening.

S…

Read more

A new joint guideline from the American Heart Association, American College of Cardiology, American Diabetes Association, and American Society of Nephrology introduces the first dedicated framework for cardiovascular-kidney-metabolic (CKM) syndrome.

The guideline recognizes that obesity, diabetes, kidney disease, and cardiovascular disease are deeply in…

Read more

A new study suggests that abdominal fat may do more than change body shape or raise BMI. In adults without cardiovascular disease at baseline, a higher waist-to-hip ratio was linked to faster biological aging across several biological clocks. The strongest signal came from metabolic aging, suggesting that belly fat may accelerate aging partly through me…

Read more

A small Nature Medicine feasibility trial found that cervical epidural spinal cord stimulation may improve arm and hand movement in people living with chronic post-stroke hemiparesis. Seven participants received temporary stimulation leads near the cervical spinal cord for four weeks.

When stimulation was turned on, motor function improved quickly, with…

Read more

A 52-week randomized trial presented at ECO 2026 found that a structured, food-based rapid weight loss program led to greater 1-year weight loss than gradual weight loss. But a related long-term diabetes-prevention study reminds clinicians and patients that obesity care should not be reduced to weight alone. Metabolic risk, insulin resistance, fatty liv…

Read more

CAR T-cell therapy, first developed for blood cancers, is now being tested in autoimmune diseases such as multiple sclerosis, lupus, stiff person syndrome, and myasthenia gravis. The most important idea is simple: instead of only suppressing inflammation again and again, researchers are testing whether engineered immune cells can remove the immune cells…

Read more

For people who feel overwhelmed by major lifestyle overhauls, this study offers a more practical message.

In a population cohort study of 59,078 UK Biobank participants, researchers found that adding about 5 minutes of sleep, nearly 2 minutes of moderate to vigorous physical activity, and a modest diet improvement such as half a serving of vegetables pe…

Read more

Migraine with aura was linked to a higher risk of ischemic stroke over about 6 years in adults aged 45 and older. Migraine without aura did not show the same signal. The most unexpected finding was in men under age 72, where migraine with or without aura was associated with a much higher stroke risk. This does not prove migraine causes stroke, but it su…

Read more

A small Italian randomized trial found that patients with advanced high-grade serous ovarian cancer who followed a short-term fasting protocol during neoadjuvant chemotherapy had lower insulin levels, higher pathologic complete response rates, and longer median progression-free survival compared with patients who continued a regular diet. The results ar…

Read more

A new study challenges the usual mental model of lacunar stroke. Researchers found that lacunar stroke and cerebral small vessel disease were not strongly linked to large artery narrowing from plaque.

Instead, they were strongly associated with abnormal widening, lengthening, and twisting of the basilar artery, a condition called dolichoectasia. This do…

Read more

A cross-sectional study of nearly 2200 dementia-free Australian adults found that higher ultraprocessed food intake was associated with lower attention scores and higher estimated dementia risk, even after accounting for Mediterranean diet adherence.

The study did not find a significant link between ultraprocessed food intake and memory scores.

Study Det…

Read more

A new first-in-human CARE study suggests that robotic colonoscopy may be technically feasible and safe in carefully selected patients. The Triton robotic colonoscopy system achieved 100% cecal intubation in 50 patients, detected polyps at rates comparable to manual colonoscopy, and allowed successful removal of eligible polyps, while potentially reducin…

Read more

For people receiving hemodialysis, getting enough protein is a daily challenge. A 12-month quality improvement study presented at the National Kidney Foundation Spring Clinical Meeting found that giving a 15-gram liquid protein supplement at the end of each dialysis session was associated with better albumin levels, improved dialysis adequacy, and fewer…

Read more